Physician profile
Daniel A Molinar
NPI 1891157236
$937.81
in general payments reported to CMS, 2019-2025
9 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.06 · 2022: $17.22 · 2023: $500 · 2024: $126 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660 · Travel and Lodging: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.75 |
| Travel and Lodging | $240.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $485.22 | 2023 | Iovera |
| Lilly USA, LLC | $107.44 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Becton, Dickinson and Company | $86.86 | 2025 | Phasix Mesh |
| Astrazeneca Pharmaceuticals LP | $75.68 | 2024-2025 | Airsupra |
| Abbvie INC. | $66.60 | 2025 | |
| Glaxosmithkline, LLC. | $63.06 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.06 | 2020 | |
| Novo Nordisk INC | $18.34 | 2025 | Wegovy |
| Amgen INC. | $14.55 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Molinar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.